



The Rising Tide of Antimicrobial Resistance: Mechanisms, Drivers, and Clinical Fallout

Suraj Kumar Sharma*

*Department of Microbiology, School of Pharmacy at Netaji Subhas University,
Jharkhand, India*

***Corresponding Author:** Suraj Kumar Sharma, Department of Microbiology, School of Pharmacy at Netaji Subhas University, Jharkhand, India.

Received: March 24, 2026

Published: July 27, 2026

© All rights are reserved by **Suraj Kumar Sharma**.

DOI: 10.31080/ASMI.2026.09.1619

Abstract

Antimicrobial resistance (AMR) represents a critical global health threat, undermining decades of progress in infectious disease management. This review synthesises current evidence on the mechanisms, drivers, and global burden of AMR, alongside emerging strategies for mitigation. A structured literature review was conducted using PubMed, Scopus, and Web of Science databases covering publications from 2010 to 2025. Findings indicate that AMR contributed to millions of deaths globally, with projections suggesting substantial increases by 2050. Mechanisms of resistance include enzymatic degradation, target modification, efflux pumps, and biofilm formation. Key drivers include antibiotic misuse, inadequate surveillance, and environmental dissemination. Despite global initiatives such as the WHO's Global Action Plan, significant gaps persist in surveillance systems, economic modelling, and One Health integration. Emerging solutions include artificial intelligence-driven diagnostics, novel antimicrobials, and microbiome-based therapies. Addressing AMR requires coordinated, multidisciplinary interventions that integrate the human, animal, and environmental health sectors.

Keywords: Antimicrobial Resistance; Multidrug Resistance; One Health; Antibiotic Stewardship; Global Burden; Drug Development

Introduction

Antimicrobial resistance (AMR) has emerged as one of the most pressing global health challenges of the 21st century. Recent global burden estimates indicate that AMR was associated with millions of deaths worldwide, with projections suggesting a substantial increase by 2050 if current trends persist [1]. The rapid evolution of resistant pathogens threatens the effectiveness of existing antimicrobial therapies, complicating treatment outcomes and increasing healthcare costs.

AMR arises through complex biological, ecological, and socio-economic processes. Despite international efforts, including the

WHO Global Action Plan, progress remains uneven due to disparities in surveillance, regulation, and healthcare infrastructure. This review aims to provide a comprehensive synthesis of AMR mechanisms, global burden, and mitigation strategies while identifying critical research gaps.

Methodology

A structured narrative review was conducted using PubMed, Scopus, and Web of Science databases. Searches included keywords such as "antimicrobial resistance," "global burden," "mechanisms," and "One Health." Inclusion criteria were:

- Peer-reviewed articles (2010–2025)
- Reviews, systematic analyses, and epidemiological studies
- English language publications

Exclusion criteria included non-peer-reviewed sources and studies lacking methodological transparency. A total of 120+ articles were screened, with priority given to high-impact journals and recent systematic reviews.

The worldwide impact of antimicrobial resistance

AMR places a significant burden on global health systems. The Global Burden of Disease study emphasises that resistant infections greatly contribute to mortality and morbidity worldwide [1]. Low- and middle-income countries (LMICs) are disproportionately affected by limited healthcare infrastructure and surveillance capabilities.

Economic repercussions are also substantial, with higher hospitalisation expenses and productivity losses. Estimates indicate that AMR could cause trillions of dollars in economic damage by 2050.

Parameter	Significant results
Mortality	Millions of deaths annually are linked to AMR.
Economic burden	Trillions USD projected by 2050
High-risk regions	LMICs, Sub-Saharan Africa, South Asia
Key pathogens	E. coli, S. aureus, K. pneumoniae

Table 1: Global Impact of AMR.

AMR develops through various biological mechanisms

- **Enzymatic Degradation:** Bacteria produce enzymes such as β -lactamases that inactivate antibiotics.
- **Target Modification:** Mutations alter antibiotic binding sites, reducing drug efficacy.
- **Efflux Pumps:** Transport proteins expel antibiotics from bacterial cells.
- **Reduced Permeability:** Altered membrane permeability limits drug entry.
- **Biofilm Formation:** Biofilms protect microbial communities from antimicrobial agents.

Mechanism	Example	Impact
Enzymatic degradation	β -lactamases	Drug inactivation
Target modification	MRSA	Reduced binding
Efflux pumps	Tetracycline resistance	Drug expulsion
Biofilms	Pseudomonas spp.	Chronic infection

Table 2: Major Resistance Mechanisms.

Drivers of Antimicrobial Resistance: Main contributors include:

- Overuse and misuse of antibiotics in humans
- Agricultural antibiotic use
- Poor infection control practices
- Environmental contamination

The One Health framework emphasises the interconnectedness of human, animal, and environmental health.

Surveillance and global initiatives

Global initiatives such as WHO GLASS and national action plans aim to combat AMR. However, surveillance systems remain fragmented, particularly in LMICs, limiting accurate burden estimation and policy implementation.

Emerging strategies and innovations

- **Novel Antibiotics:** Development of new antimicrobial agents remains limited but critical.
- **Artificial Intelligence:** Machine learning models improve resistance prediction and diagnostics.
- **Microbiome-Based Therapies:** Restoring microbial balance offers alternative treatment approaches.
- **CRISPR-Based Interventions:** Gene-editing tools show promise in targeting resistant bacteria.

Research gaps and future directions

Identified main gaps

- Lack of standardised global surveillance systems
- Insufficient data from LMICs
- Limited economic burden modelling
- Underrepresentation of environmental AMR




Figure 1: Conceptual diagram of AMR drivers and outcomes.

Mechanisms of Resistance



Figure 2: Mechanisms of Resistance.

- Weak integration of One Health approaches
- Slow development of new antibiotics

Future directions

- Strengthening global surveillance networks
- Investment in antibiotic R&D
- Integration of AI in diagnostics
- Environmental monitoring frameworks

Conclusion

AMR represents a multifaceted global crisis that requires urgent, coordinated action. While significant progress has been made in

understanding resistance mechanisms and developing mitigation strategies, critical gaps remain in surveillance, research, and policy implementation. A comprehensive, multidisciplinary approach is essential to curb the growing threat of AMR [2-13].

Description of the Research

Antimicrobial resistance (AMR) represents a critical global health threat, undermining decades of progress in infectious disease management. This review synthesises current evidence on the mechanisms, drivers, and global burden of AMR, alongside emerging strategies for mitigation. A structured literature review was conducted using PubMed, Scopus, and Web of Science databases covering publications from 2010 to 2025. Findings indicate that AMR contributed to millions of deaths globally, with projections suggesting substantial increases by 2050. Mechanisms of resistance include enzymatic degradation, target modification, efflux pumps, and biofilm formation. Key drivers include antibiotic misuse, inadequate surveillance, and environmental dissemination. Despite global initiatives such as the WHO's Global Action Plan, significant gaps persist in surveillance systems, economic modelling, and One Health integration. Emerging solutions include artificial intelligence-driven diagnostics, novel antimicrobials, and microbiome-based therapies. Addressing AMR requires coordinated, multidisciplinary interventions that integrate the human, animal, and environmental health sectors.

Bibliography

1. Naghavi M., *et al.* "Global burden of bacterial antimicrobial resistance 1990–2021". *The Lancet* (2024).
2. Okeke IN., *et al.* "The scope of the antimicrobial resistance challenge". *The Lancet* (2024).
3. Belay W Y., *et al.* "Mechanism of antibacterial resistance". *Frontiers in Pharmacology* (2024).
4. Chong C E., *et al.* "AMR conference report". *npj Antimicrobials and Resistance* (2024).
5. Sharma S., *et al.* "From ayurveda to evidence-based medicine: A translational review of gymnema sylvestre". *International Journal of Pharmaceutical Chemistry and Analysis* 12.2 (2025): 110-115.

6. Marino A., *et al.* "Global burden of multidrug-resistant bacteria". *Epidemiologia* (2025).
7. Oliveira M., *et al.* "Advances in antimicrobial resistance". *Microorganisms* (2024).
8. Birlutiu V., *et al.* "Epidemiology of multidrug resistance". *Microorganisms* (2024).
9. Sharma SK., *et al.* "Moringa oleifera as a natural antimicrobial agent: A phytochemical and microbiological investigation". *African Journal of Medicine and Pharma Research* 3.1 (2025): 28-37.
10. Kumar H., *et al.* "Trends in AMR". *Journal of Infection* (2025).
11. Painter C., *et al.* "Sustainable AMR surveillance". *The Lancet Infectious Diseases* (2025).
12. Suraj Kumar Sharma., *et al.* "Analysis of Drug Metabolism". *Acta Scientific Pharmaceutical Sciences* 9.4 (2025): 56-61.
13. Lewnard JA., *et al.* "AMR burden in LMICs". *The Lancet* (2024).